title: Histopathological prognostic factors in medulloblastoma: high expression of survivin is related to unfavourable outcome.
abstract: Standard postoperative treatment of medulloblastoma consists of craniospinal irradiation and chemotherapy. Currently, only clinical factors are used for therapy stratification. To optimise treatment and patient outcome, biological prognostic markers are needed. In the present study we tested the prognostic influence of four histopathological parameters considered in recent publications as prognostic factors in medulloblastoma. We analysed a series of 82 Austrian medulloblastoma patients who were treated according to the consecutive HIT protocols for medulloblastoma conducted by the German Society of Paediatric Haematology and Oncology. Histological subtype and immunohistochemical expression of erbB-2, TRKC, and survivin were determined on paraffin embedded tumour tissue and correlated with patient outcome. Statistical analysis showed a significant correlation of high expression levels of survivin with decreased survival. None of the other investigated histopathological factors correlated significantly with patient outcome. Our data indicate that high survivin expression is related to unfavourable clinical outcome in medulloblastoma patients.
authors.affiliation: Institute of Neurology, Medical University of Vienna, Währinger Gürtel 18-20, A-1097 Vienna, Austria. christine.haberler@meduniwien.ac.at <christine.haberler@meduniwien.ac.at>
authors.forename: C
authors.initials: C
authors.lastname: Haberler
authors.forename: I
authors.initials: I
authors.lastname: Slavc
authors.forename: T
authors.initials: T
authors.lastname: Czech
authors.forename: E
authors.initials: E
authors.lastname: Gelpi
authors.forename: H
authors.initials: H
authors.lastname: Heinzl
authors.forename: H
authors.initials: H
authors.lastname: Budka
authors.forename: C
authors.initials: C
authors.lastname: Urban
authors.forename: M
authors.initials: M
authors.lastname: Scarpatetti
authors.forename: G
authors.initials: G
authors.lastname: Ebetsberger-Dachs
authors.forename: C
authors.initials: C
authors.lastname: Schindler
authors.forename: N
authors.initials: N
authors.lastname: Jones
authors.forename: A
authors.initials: A
authors.lastname: Klein-Franke
authors.forename: H
authors.initials: H
authors.lastname: Maier
authors.forename: B
authors.initials: B
authors.lastname: Jauk
authors.forename: A
authors.initials: A
authors.lastname: Kiefer
authors.forename: J A
authors.initials: JA
authors.lastname: Hainfellner
mesh_terms: D000293:Adolescent; D000328:Adult; D002528:Cerebellar Neoplasms / Q000401:mortality / Q000473:pathology*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007223:Infant; D007231:Infant, Newborn; D051034:Inhibitor of Apoptosis Proteins; D008297:Male; D008527:Medulloblastoma / Q000401:mortality / Q000473:pathology*; D008869:Microtubule-Associated Proteins / Q000378:metabolism*; D009363:Neoplasm Proteins / Q000378:metabolism*; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D020812:Receptor, trkC / Q000378:metabolism; D016019:Survival Analysis; D000077022:Survivin
chemical_list: D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D020812:Receptor, trkC; D000077022:Survivin; C107489:BIRC5 protein, human